Pharmacologic management of diabetic peripheral neuropathic pain

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 13, 2013, Pages 1765-1775

  Iyer, Shridhar ^a   Tanenberg, Robert J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Diabetic neuropathy; Duloxetine; Neuropathic pain; Peripheral neuropathy; Pregabalin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMITRIPTYLINE; CAPSAICIN; CARBAMAZEPINE; CLONIDINE; DULOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LIDOCAINE; MORPHINE; OXYCODONE; PREGABALIN; TOPIRAMATE; TRAMADOL; VENLAFAXINE;

ACUTE KIDNEY FAILURE; ALLODYNIA; ANALGESIA; APPETITE; BLOOD PRESSURE; BURNING SENSATION; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DRUG DOSE TITRATION; DRUG MEGADOSE; EYE DISEASE; FOOT PAIN; GLAUCOMA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART RHYTHM; HUMAN; HYPERGLYCEMIA; HYPERTHERMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDLINE; MONOTHERAPY; MYOPATHY; NAUSEA; NOCICEPTIVE PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; QT PROLONGATION; REVIEW; RHABDOMYOLYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SWEATING; URINE RETENTION; VASODILATATION; VIBRATION SENSE; WEIGHT GAIN;

EID: 84881621528     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.811490     Document Type: Review

References (80)

1. Diabetes fact sheet. 2011.Available from: http://www.who. int/mediacenter/factsheets/fs312/en/index. html [Last accessed 12 January 2013]
2. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999;7:245-52
3. Soedamah-Muthu SS, Chaturvedi N, Witte DR, et al. EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008;31:1360-2366
4. Ziegler D, Rathmann W, Dickhaus T, et al. for the KORA Study Group. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31:464-9
5. Galer BS, Giana A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Prac 2000;47:123-8
6. Benbow SJ, Chan AW, Bowsher D, et al. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1993;11:17-21
7. Dyck PJ, Litchy WJ, Lehman KA, et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45:1115-21
8. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008;120:1-34
9. Lee JH, Cox DJ, Mook DG, McCarty RC. Effects of hyperglycemia on pain threshold in alloxan-diabetic rats. Pain 1990;40:105-7
10. Morley GK, Mooradian AD, Levine AS, Morley JE. Mechanism of pain in diabetic peripheral neuropathy. Am J Med 1984;77:79-82
11. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy or rapid glycemic control (insulin neuritis). Diabetologia 1984;39:329-35
12. Obrosova IG. Diabetes and the peripheral nerve. Biochim Biophys Acta 2009;1792:931-40
13. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy; a review. J Diabetes Complications 2010;24:354-60
14. Boulton AJM, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982;5:386-90
15. Scadding JW. Development of ongoing activity, mechano-sensitivity and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol 1981;73:345-64
16. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011;27:629-38
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
18. Genuth S. Insights from the diabetes control and complications trial: epidemiology of diabetes interventions and complication study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006;12:34-41
19. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
20. Martin C.L, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340-4
21. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012;11:521-34
22. Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000;23:1227-31
23. Ting RZW, Szeto CC, Chan MHM, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-9
24. Andrès E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. Arch Intern Med 2002;162:2251-2
25. Gilligan MA. Metformin and vitamin B12 deficiency. Arch Intern Med 2002;162:484-5
26. Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes 2011;4:289-305
27. Stevens MJ, Li F, Drel VR, et al. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin-diabetic rats. J Pharm Exp Ther 2007;320:458-64
28. Ziegler D. Painful diabetic neuropathy. Diabetes Care 2009;32(Suppl 2):S414-19
29. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis 2001;3:53-62
30. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706
31. Boulton AJM, Malik RA, Arezzo J, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86
32. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano CO. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5:215-18
33. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311:1047-52
34. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505-9
35. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004;63:865-73
36. Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes-a randomized placebo controlled study. Acta Neurol Scand 2002;106:248-52
37. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6
38. Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251-2
39. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71
40. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19:149-77
41. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
42. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20
43. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65
44. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007;29:2536-46
45. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18
46. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Inter Med 1999;159:1931-7
47. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448-54
48. Pfizer Protocol No. 1008-040: A placebo-controlled trial of pregabalin and amitriptyline for treatment of painful diabetic peripheral neuropathy [article online]. 2007.Available from: http://www.clinicalstudyresults.org/ drugdetails/drug-name-id-203&sort-c.company-name&page-2&drug-id- 1952 [Last Accessed 28 June 2007]
49. Rosenstock J, Tuchman M, La Moreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
50. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60
51. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain 2005;115:254-63
52. Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-13
53. Rosenstock J, Arezzo J, Pauer L, et al. Pfizer Global R&D: pregabalin as treatment of painful diabetic peripheral neuropathy (DPN): nerve conduction and analgesic effect in a 13-week double-blind, placebo-controlled trial (Poster). Pain 2007;8(Suppl 1):S27
54. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10
55. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
56. European Association for the Study of Diabetes (EASD) 48th Annual Meeting: abstract 48. Presented October 2, 2012.
57. Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011;86:615-26
58. Yarnitsky D, Granot M, Nahman-Averbuch H, et al. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153:1193-8
59. Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle Curr Diab Rep 2012;12:403-13
60. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113
61. Bellows BK, Dahal A, Jiao T, Biskupiak J. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother 2012;26:153-64
62. Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly 2010;140:297-306
63. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-6
64. Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8
65. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-34
66. Mousa SA, Shaqura M, Khalefa BI, et al. Rab7 Silencing prevents-opioid receptor lysosomal targeting and rescues opioid responsiveness to strengthen diabetic neuropathic pain therapy. Diabetes 2013;62:1308-19
67. Kozma CM, Benson C, Slaton TL, et al. Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy. Curr Med Res Opin 2012;28:1485-96
68. Yao P, Meng LX, Ma JM, et al. Sustained-release oxycodone tablets for moderate to severe painful diabetic peripheral neuropathy: a multicenter, open-labeled, postmarketing clinical observation. Pain Med 2012;13:107-14
69. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987;147:1442-4
70. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992;15:159-65
71. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991;151:2225-9
72. Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992;15:8-14
73. Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. 0.025% Capsaicin gel for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial. Pain Pract; 2012
74. Martini C, Yassen A, Olofsen E, et al. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza-) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res 2012;5:51-9
75. Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012;153:1815-23
76. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21
77. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf
78. Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220
79. Sadosky A, Schaefer C, Mann R, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. Diabetes Metab Syndr 2013;6:79-92
80. Tanenberg RJ, Clemow DB, Giaconia JM, Risser RC. Duloxetine compared with pregabalin for diabetic peripheral neuropathic pain management in patients with suboptimal pain response to gabapentin and treated without antidepressants: a post hoc analysis. Pain Pract 2013